This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Loebinger, M. Articles by Wilson, R Search for Related Content PubMed PubMed Citation Articles by Loebinger, M. Articles by Wilson, R Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB CALCITONIN, SALMON Social Bookmarking                         What's this?

Procalcitonin in stable and unstable patients with bronchiectasis

Host Defence Unit, Royal Brompton Hospital, London, UK mloebinger{at}doctors.org.uk

A Shoemark

Host Defence Unit, Royal Brompton Hospital, London, UK

M Berry

Biochemistry Department, Royal Brompton Hospital, London, UK

M Kemp

Host Defence Unit, Royal Brompton Hospital, London, UK

R Wilson

Host Defence Unit, Royal Brompton Hospital, London, UK

Presently used markers of infection in bronchiectasis are inadequate to judge stability or make decisions about antibiotic treatment during bacterial exacerbations. Procalcitonin (PCT) is a new marker that has been used in community-acquired pneumonia and promises to allow much more specific and sensitive monitoring of patients with bacterial infections. This is the first study assessing its use in bronchiectasis. Thirty-eight consecutive inpatients and 63 consecutive outpatients were included in the study. All patients had PCT, other inflammatory markers, and a symptom score recorded. Inpatients had these values repeated at day 5 and 10 of their stay, while receiving intravenous antibiotics. Outpatients: PCT levels were generally low in the outpatient group. PCT was significantly correlated to C-reactive protein. Higher levels were associated with increased symptoms (P = 0.09) and an increased likelihood of antibiotic prescription (P = 0.007). Inpatients: As a group, inflammatory markers were significantly higher than in the outpatient group (P = 0.007). There was no correlation between the levels of PCT and the other inflammatory markers. PCT concentrations were generally low (as with other markers), which may reflect mucosal infection. Larger studies are needed, but PCT seems unlikely to be able to guide treatment of an exacerbation in bronchiectasis. PCT may offer more promise as a measure of stability.

Key Words: bronchiectasis • biomarker • exacerbation • infection • procalcitonin

Chronic Respiratory Disease, Vol. 5, No. 3, 155-160 (2008)
DOI: 10.1177/1479972308088823


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?